Turn Biotechnologies Names 25-year Biotech Industry Veteran Richard Peterson Chief Financial Officer

Turn Biotechnologies Names 25-year Biotech Industry Veteran Richard Peterson Chief Financial Officer
share Share

Seasoned Executive has Successful Track Record Working with Global Investors to Raise Billions of Dollars

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions announced it has appointed Richard "Ric" Peterson as chief financial officer.

Mr. Peterson, who has served as CFO of numerous public and private biotech and pharmaceutical companies, has deep experience with private financing, public offerings, and complex global transactions. He will oversee all financial functions and fundraising efforts as Turn Bio prepares to launch its clinical programs.

"Ric's background with biotech companies in various stages of development and his experience as a financial and business leader will be great assets as Turn Bio moves into the next phases of growth," said company CEO Anja Krammer. "As Turn Bio progresses toward the clinic, Ric will enhance our team's expertise and help communicate our unique vision for treating the diseases of aging within the investment community."

During his 25 years of serving as a chief financial officer, Peterson has led traditional fundraising efforts for pre-clinical, clinical and commercial companies, managed initial public offerings and overseen corporate purchases and sales. He has completed more than 40 transactions representing billions of dollars.

"I am excited to join the team at Turn Bio at this important stage, when the company's potential for growth and value creation is exceptional," said Peterson. "The talented team of executives and cell rejuvenation pioneers has brought Turn Bio successfully to this point, achieved breakthroughs in epigenetic reprogramming and developed a game-changing delivery system that overcomes the leading obstacle to cell therapies.  I look forward to helping steer the next stage of our growth."

Peterson has worked with several clinical stage biopharmaceutical companies, including Clarus Therapeutics, Sienna Biopharmaceuticals, Dermavant Sciences Inc., and Novan Inc. He was also CFO of Medicis Pharmaceutical Corporation, a commercial pharmaceutical company. Under Peterson's guidance, Novan and Sienna completed successful IPOs. At Medicis, he helped lead the company's growth, which resulted in its acquisition for $2.6 billion by Valeant Pharmaceuticals International.

Peterson serves as a director at Universal Insurance Holdings, where he chairs the Board's Audit Committee.

Source: Turn Biotechnologies

«« The NHS Announced Cutting-Edge Laser to Treat Epilepsy

World Stroke Day and The Importance of Preventive Healthcare »»

Published on : Wed, 2 Nov 2022

Related Articles

Inteleos , a non-profit global healthcare certification organization, today announced the appointment of Wendy Reeling, CPA,... Read more

Mardi C. Dier joins as Chief Financial Officer and Chief Business Officer Mina Kim joins as Chief Legal and Administrative... Read more

Acute virtual care leader hires new chief financial officer, chief marketing officer, chief people officer, and chief product... Read more

Turn Biotechnologies,Richard Peterson,chief financial officer Turn Biotechnologies Names 25-year Biotech Industry Veteran Richard Peterson Chief Financial Officer

No comment

Please login to leave a comment...

Highlighted Products